Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Richard Moscicki joins FDA

Provides regulatory agency with more than 20 years of industry experience

FDA, Richard MoscickiThe US Food and Drug Administration (FDA) has appointed Genzyme's Dr Richard Moscicki to the newly created position of deputy centre director for science operations at its Center for Drug Evaluation and Research (CDER).

Dr Moscicki, who currently serves as senior VP, head of clinical development at Sanofi's Genzyme division, will help lead the CDER in its role to regulate over-the-counter and prescription-only drugs available in the US.

The FDA will benefit from his strong industry background in research, which includes time spent as medical director and chief medical officer at Genzyme.

He also gained regulatory and pharmacovigilance experience at the US-based biotech, serving as its senior VP of biomedical and regulatory affairs from 1996 to 2011.

In his role at the FDA, Dr Moscicki will work with Dr Bob Temple, deputy director for clinical science, and Dr Doug Throckmorton, deputy director for regulatory programmes.

14th February 2013

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics